Rheumatology Insights: October 2021 - Cardinal Health Specialty Solutions - Views on industry trends impacting rheumatology practices nationwide
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Cardinal Health Specialty Solutions Rheumatology Insights: October 2021 Views on industry trends impacting rheumatology practices nationwide
A message from leadership
Heidi Hunter
Welcome to our second edition of Rheumatology Insights, a research-
based report designed to provide perspectives on key issues and trends
affecting rheumatology practices nationwide.
As someone who has spent a good portion of my career working in
rheumatology, I’ve seen firsthand how this therapeutic area has changed.
Over the past decade, the demand for rheumatology care has grown
steeply as the population has aged, while at the same time, the pressures
and complexities facing rheumatology practices have increased.
Our new report seeks to understand how rheumatologists are managing
these changing dynamics. We explored their perspectives on the impact
of COVID-19, how new reimbursement policies are affecting clinical
treatment and practice operations, and the role that technology and AI
may play in the future of rheumatology care.
The research shared in this issue was fielded using web-based surveys
from July through September 2021. More than 85 rheumatologists from
a mix of community- and hospital-based practices throughout the U.S.
participated in the research.
At Cardinal Health, we believe that understanding the needs of
healthcare providers is key to the delivery of better patient care. We hope
you find the insights in the enclosed report to be as valuable as we do.
Sincerely,
Heidi Hunter
President, Cardinal Health Specialty Solutions
2 3
COVID-19
At the time our first Rheumatology Insights
report was published in June 2020, COVID-19
was widely viewed as an acute health crisis
that healthcare providers and patients would
need to manage through for several months
until healthcare could return to “normal.”
Today, as the U.S. continues to wrestle with new variants of the virus and resurging
infection rates, there is broad consensus that COVID-19 will have long-term
implications on how healthcare is delivered across all therapeutic areas.
The evidence of COVID-19’s impact on rheumatology was clearly seen during the 2020
American College of Rheumatology Meeting, in which numerous abstracts examined
how rheumatologists’ use of telemedicine has evolved,1 and several posters explored
how smartphone apps have been used to support telemonitoring of rheumatic
disease activity2 during the pandemic.
As COVID-19 continues to create challenges for rheumatology practices, we were
curious to understand rheumatologists’ views on the long-term implications of the
Assessing the
virus, and to know how patient needs and care protocols have changed. We also
wanted to learn whether the pandemic is continuing to impact the financial and
operational performance of rheumatology practices.
impacts of COVID-19
on rheumatology
practices and
4
patient care 5
COVID-19 has shifted the paradigm of care for rheumatologists COVID-19
OUR VIEWPOINT
FINANCIAL IMPACT: More than 4 in 10 rheumatologists surveyed
Gordon K. Lam, MD, FACR said the financial health of their practices is not as strong as it
Medical Director of Clinical Research was before the pandemic, though new patient referrals are stable
Arthritis & Osteoporosis Consultants of the Carolinas
or increased.
The responses to our COVID-19 survey questions reflect the significant impact
the pandemic has had on rheumatologists and their patients over the past Which of the following best describes the financial health of your practice today?
year and a half. The adoption of telemedicine services is perhaps most notable.
According to our survey, only 16% were using telemedicine services before the The financial health of our practice is not as strong today as it was before the pandemic
start of the pandemic, but almost all practices adopted it in 2020. In addition,
93% of surveyed respondents say they expect some portion of patient visits 43%
will continue to be managed via telemedicine after the end of the pandemic.
The financial health of our practice is about the same today as it was before the pandemic
Although all rheumatologists would probably agree that in-person patient
visits are always preferrable to virtual appointments, telemedicine has 46%
enabled rheumatologists to maintain continuity of care during the pandemic,
has provided a way to see patients who might not otherwise be able to The financial health of our practice is better today than it was before the pandemic
receive care, and has created a new mechanism for reimbursement. An
overwhelming majority (90%) of survey participants said they expect to use 11%
telemedicine to see patients who lacked transportation, 46% would use it to
see immunocompromised patients, and another 41% expect to use it to triage N = 87
patients in emergency situations.
In regard to new patient volume, 79% of surveyed rheumatologists say they Which of the following best describes your new patient referral volume today compared
are seeing the same amount or more patients than they did before the to pre-pandemic?
pandemic, while 21% say they are seeing fewer patients. The 21% is surprising
given that demand for rheumatology services nationwide has continued to We are seeing fewer new patient referrals today than before the pandemic
increase. This may reflect the ongoing impact of COVID-19 and could suggest
that some patients may be continuing to delay healthcare needs that are not 21%
viewed as urgent – or that referring physicians are simply too busy treating
COVID patients to refer patients for rheumatology treatment. We are seeing similar levels of new patient referrals as before the pandemic
One important trend that is not reflected in the research is how rheumatology 42%
treatments may shift due to their overlap with acute COVID infections and to
their possible interactions with vaccines. The pandemic has led to shortages We are seeing more new patient referrals today than before the pandemic
of certain medications, like IL-6 inhibitors, and research has shown that
several commonly used treatments, such as methotrexate, rituximab, and 37%
mycophenolate, may affect a patient's humoral response to the COVID-19
vaccine.3 These effects may impact rheumatologists' treatment decisions, and N = 87
their recommendations on the timing of the vaccine doses.4 Clearly, these will
be important trends to watch over the coming months.
79% of participating rheumatologists
said new patient referrals are the same or greater
than before the pandemic.
6 7
COVID-19 COVID-19
TELEMEDICINE: Nearly two-thirds of participating rheumatologists For what purposes will you use telemedicine in the future?
said the pandemic caused them to adopt new approaches they will To see patients who lack transportation to appointments 90%
continue to use long term, such as telemedicine. To see patients who are immunocompromised 46%
Which of the following most aligns with your view on how the COVID-19 pandemic To triage patients who may need emergency care 41%
impacted patient care in your practice?
N = 81
The pandemic led us to adopt new approaches to patient
care, some of which we will maintain over the long term 58%
The pandemic had a temporary impact on how we
treated patients, but it has not had a long-term impact 39%
The pandemic had very little impact on patient care
3%
N = 87
Before the COVID-19 pandemic, what percentage of your patient visits were conducted
via telemedicine? After the end of the pandemic, what percentage of your patient visits
do you anticipate will be conducted via telemedicine?
Before pandemic
After pandemic
4%
84% 7% 10% 45% 26% 1% 14% 1% 8% While few practices were using telemedicine before the pandemic,
N = 87
None 1-10% 11-20% 21-30% 31% or more
93% 93% of participating rheumatologists
said they will continue to use it in the future, particularly with
patients who lack transportation to appointments.
8 9
COVID-19
IMPACT ON PATIENT CARE: 90% of rheumatologists surveyed
said the social and economic challenges posed by COVID-19 have
negatively impacted patients, with mental health support cited as
the most pressing unmet patient need.
Please indicate your degree of agreement with this statement. Social and economic
challenges created by the COVID-19 pandemic (including higher unemployment, social isolation,
etc.) have had a negative impact on the health of my patients.
N = 87
31% 59% 9% 1% 0%
Strongly agree Agree Neither agree Disagree Strongly disagree
nor disagree
What gaps or unmet needs in patient care have been revealed by the COVID-19
pandemic? Please select all that apply.
Mental health support 83%
Medication adherence support 61%
Support navigating insurance coverage/managed care 55%
Support with managing the cost of their therapy 52%
Caregiver support 43%
Other 5%
I do not see any significant gaps/unmet needs in patient care 1%
N = 87
10 11
INDUSTRY DYNAMICS
Although the COVID-19 pandemic created
unique challenges for rheumatology
providers, the landscape for rheumatology
practices has also been complicated by
new clinical developments and changes in
reimbursement policies.
The continuing shift from fee-for-service reimbursement to value-based reimbursement has
been a significant challenge for rheumatology practices for several years, as demonstrated
by our 2020 Rheumatology Insights survey. This year, to add to the complexity, the Centers
for Medicare & Medicaid Services (CMS) released a new average sales price (ASP) calculation
methodology for self-administered drugs,5 resulting in reimbursement decreases for several
therapies that are commonly prescribed by rheumatologists.
At the same time, rheumatologists are seeing a shift in the mix between infused therapies
and oral therapies. This impacts reimbursement because infused medicines are purchased
on a “buy and bill” model, meaning providers are reimbursed for the ASP of the therapy plus
6%. During the COVID-19 pandemic, some rheumatologists shifted immunocompromised
patients to oral therapies to avoid additional clinic visits. However, a new FDA black box
warning on some oral therapies for arthritis6 and recent shortages of other medications7
may result in a shift back to infused medicines.
Our survey sought to understand how rheumatologists are thinking about these issues, and
Responding to
what steps they are taking to help their practices respond to the challenges.
changing industry
and reimbursement
12
dynamics 13
Declining reimbursement continues to challenge rheumatologists,
and many do not have a plan for replacing lost revenue INDUSTRY DYNAMICS
OUR VIEWPOINT
CRITICAL CHALLENGES: Value-based care and changing
Gordon K. Lam, MD, FACR reimbursement models were cited as the biggest challenges
Medical Director of Clinical Research facing rheumatology practices, along with lack of providers and
Arthritis & Osteoporosis Consultants of the Carolinas
increasing administrative duties.
The rheumatology landscape has shifted over the past year – but the results of
our survey show that 28% of rheumatologists still perceive value-based care Which of the following do you consider to be the biggest challenge facing your practice?
and changing reimbursement models as the top challenges, consistent with
29% in 2020. Interestingly, fewer survey participants said they see increasing 2021 2020
administrative duties as a top challenge: 24% in 2021 vs. 33% in 2020.
N = 87 N = 102
Although declining reimbursement is seen as a top challenge, it is not
apparent that many rheumatologists have a clear plan on how to effectively
respond or counteract that trend. According to the study, 59% said
reimbursement changes to self-administered drug products would have a
significant negative or somewhat negative impact on their practice, yet more
than a third of respondents (38%) said they were either unsure how they
would mitigate the impact or would not take steps to mitigate.
The survey also indicated that many rheumatology practices may be missing
opportunities to strengthen their financial performance by adding new
revenue streams. Expanding infusion services to therapeutic areas outside of
rheumatology has become an increasingly recognized revenue-generating
strategy for many practices, yet nearly half (46%) of our participants said they
infuse rheumatology patients only and another 15% said they do not have an
infusion center.
Perceptions about the impact of oral therapies on rheumatology practices
28% 29% 18% 15% 24% 33%
was mixed with 28% saying they do not expect much impact, 46% saying they Value-based care and the changing Lack of providers to support the Increasing administrative and
expect to do fewer infusions, and 26% saying they are unsure what the impact reimbursement landscape growing number of patients practice management duties
will be. While research shows that patients prefer oral therapies over infused
therapies,8 the recent FDA announcement about black box warnings for JAK
inhibitors9 and the shortage of tocilizumab due to the pandemic surge,10
both of which occurred after this survey was completed, will likely affect
rheumatologists’ treatment decisions in the near term.
On the whole, the survey results indicate that rheumatologists and their
administrators may need to put more focus on revenue management to
maintain financial performance, as reimbursement pressures are likely to
intensify in the future.
10% 8% 15% 10% 5% 5%
Increasing healthcare Lack of time to spend on Competition
costs for patients patient care
14 15
INDUSTRY DYNAMICS INDUSTRY DYNAMICS
As the U.S. population ages, demand for rheumatology services is expected to grow while A growing number of oral therapies for rheumatology are in the drug development pipeline.
the number of practicing rheumatologists is expected to decrease. How does your practice As more oral therapies come to market, how do you see your practice changing?
expect to manage these changing dynamics? Please select your top 3.
2021 2020
N = 87 N = 102
37% 28% 26% 9%
We expect to perform fewer We do not expect any I am not sure how more We expect to perform fewer
infusions and subcutaneous major impact over the oral therapies will impact infusions and subcutaneous
injections and expect to see next several years my practice injections and will explore
in-practice dispensing or
a decrease in revenue
adding a specialty pharmacy
47% 57% 31% 20% 32% 34% 30% 34%
Hire more advanced Hire more Expand patient care Invest in technology/
practice providers/ administrative staff with telemedicine tools to enable providers
clinicians to spend more time on
patient care
16% 14% 15% 23% 10% 8% 8% 11%
Extend hours to provide Postpone retirement Use consulting services Sell or merge the practice
patient services on evenings to aid with practice
and/or weekends management
Nearly one third of rheumatologists say they expect to Almost 4 in 10 participating rheumatologists said they
hire more administrative staff, up from just expect to perform fewer infusions and injections
20% a year ago. as more oral therapies arrive on the market.
16 17
INDUSTRY DYNAMICS INDUSTRY DYNAMICS
DECLINING REIMBURSEMENTS: About 60% of rheumatologists This year, the Centers for Medicare & Medicaid Services (CMS) announced reimbursement
changes for certain Medicare Part B drugs (such as Orencia® and Cimzia®) that have self-
surveyed said reimbursement has declined, though some have administered formulations. How much of a negative impact will this adjustment have on
adapted by adding new sources of revenue. your practice this year?
Which of the following best describes your view of the reimbursement landscape
in rheumatology?
14%
47% 37% 2%
Reimbursement for my
practice has declined over
We have not seen a
significant change
Reimbursement has
declined, but my practice
Reimbursement for my
practice has increased
20% 39% 17% 11% 13%
the past year in reimbursement has counterbalanced over the past year
these changes by adding Significant Somewhat Very little No impact Not sure
over the past year
new sources of revenue negative impact
negative impact negative impact
N = 87
N = 87
What strategies will you implement to mitigate this negative impact? Please select all that apply.
Explore other new revenue streams 33%
Start new patients on different drug therapies 27%
Move existing patients to different drug therapies 23%
Change my payer mix/Limit the number of Medicare patients 11%
Unsure 18%
I do not anticipate making any changes to mitigate the impact 20%
N = 66
18 19INDUSTRY DYNAMICS INDUSTRY DYNAMICS
MULTI-SPECIALTY PRACTICES: About 1 in 3 rheumatologists PATHWAY PROGRAMS: Only about 1 in 4 rheumatologists surveyed
surveyed said they infuse patients from other specialties, primarily said their practice participates in commercial payer or health plan-
to address community need. sponsored pathway programs, but 14% said they are considering it
for the future.
Which of the following best describes your current practice?
Does your practice participate in any commercial payer or health plan-sponsored
pathway programs?
62 % 24 % 14 %
5%
46% 34% 15%
No, we do not currently participate Yes, we currently participate in No, but we plan to participate in
We infuse rheumatology We are a multi-specialty We don’t have our own We currently infuse in pathway programs pathway programs pathway programs in the future
patients only infusion practice, infusing infusion center; we refer rheumatology patients
both rheumatology and our patients to a multi- only, but are considering
N = 87
specialty infusion center expansion into other
patients treated for other
specialties
diseases
N = 87
83% of “Supports a need in
rheumatologists my community” (35%)
with multispecialty was the most cited reason
practices said they for expanding into other
provide infusions for specialties but driving Among practices in pathway programs,
gastroenterology
additional revenue (18%) participating rheumatologists
and mandates from practice cited limited availability of programs (28%), finding
patients. owners (18%) were also the patients to participate (26%) and managing data
Dermatology (47%), mentioned. and reporting (20%) as the biggest challenges.
immunology (43%) and
neurology (40%) were N = 34
also commonly cited.
N = 30
20 21AI / MACHINE LEARNING
As the industrywide shortage of
rheumatologists continues to challenge both
patients and providers, technology and artificial
intelligence (AI) are poised to potentially
reduce resource burdens and help support
diagnosis and patient treatment decisions.
The 2020 American College of Rheumatology Meeting featured several abstracts and posters
exploring the use of technology in practice, including studies using AI-driven methodologies
for X-ray data analysis11 and a study that examined whether machine learning can more
effectively identify clinical features and biomarkers to predict response to key treatments.12
In addition, as telemonitoring of rheumatology patients has become more common
during the COVID-19 pandemic, some researchers are studying the role that digital health
technology, such as wearables and apps, can play in supporting better health.13
The emerging research around these technologies and the early adoption of AI-based
tools in other therapeutic areas suggest there could be a significant opportunity to use
AI to enhance rheumatology care in the future. Our survey is intended to gauge whether
rheumatologists are following these technology trends and if they see the same potential
for AI in the years ahead.
Technology use
and the future
outlook for AI in
22
rheumatology 23Rheumatologists lack familiarity with artificial intelligence and
machine learning and are skeptical about the value of these tools AI / MACHINE LEARNING
OUR VIEWPOINT
CURRENT TECHNOLOGY USE: Almost all rheumatology practices
Amy Valley, PharmD surveyed use electronic health records (EHRs), and nearly 4 in 10
Vice President, Clinical Strategy and Technology Solutions said they are likely to make further investments in EHRs in the
coming year.
Advances in technology may have the potential to significantly alleviate Which of the following technology solutions do you currently use in your practice? Which
some of the pressures facing rheumatologists. Yet our survey shows most of the following technology solutions do you expect to invest in during the coming year?
rheumatologists have low awareness of these innovations and limited Please select all that apply.
confidence in the ability to drive change.
Despite increased use of artificial intelligence (AI) in rheumatology, more Electronic health records
than half of survey respondents (56%) said they are not very familiar with the
use of AI and machine learning in healthcare, and less than a quarter (24%) 97%
of respondents believe AI will have a significant impact on rheumatology 39%
care over the next three years. In addition, only about a quarter (27%) say
they can envision AI playing an important role in informing their treatment Inventory management system
decisions in the future. These results are somewhat surprising when
considering the growing body of research showing the application of AI to 13%
evaluate rheumatologic diseases and to predict how it will progress.
10%
In addition, when asked about future applications of AI and machine
learning, less than half (41%) say it is likely or very likely that they will drive Practice management system
operational efficiencies for rheumatology practices, and far fewer say it is
likely that AI and machine learning will help to improve the quality of care 25%
(33%) or lower healthcare costs (25%). 24%
Interestingly, many of the challenges facing rheumatologists today may
eventually be addressed by AI-powered solutions. As our survey shows, Infusion management tool
rheumatologists continue to cite declining reimbursement as their
top challenge, and AI is increasingly being used within revenue cycle 17%
management tools to increase efficiency and make financial management 19%
more predictable. We are also seeing a growing use of AI in population
health tools, which can be used to guide clinical decisions, such as which Analytics and reporting tools
patients are likely to be adherent to their treatment plan or to experience
clinical deterioration. These tools may help providers identify patients who 25% Solutions in place
need proactive interventions or additional supportive services.
24% Likely to invest in coming year
Overall, our survey suggests there is a need for more education around
the role that technology can play in supporting rheumatologists. Those N = 87
providers who embrace the opportunities early may see advantages in both
clinical care delivery and the financial performance of their practice.
About 40% of participating rheumatologists
plan to invest in EHRs in the coming year though nearly all
have a system in place.
24 25AI / MACHINE LEARNING
NEAR-TERM OUTLOOK ON AI: Most rheumatologists surveyed
said they have limited familiarity with artificial intelligence (AI)/
machine learning in healthcare and see minimal impact over the
next three years.
How familiar are you with the use of AI/machine learning in healthcare?
11 %
Very familiar
33 %
Moderately familiar
56 %
Not very familiar
N = 87
What impact do you expect AI/machine learning to have on rheumatology care over the
next three years?
24% 53% 23%
Over 75% of rheumatologists surveyed predicted Significant impact. A considerable Limited impact. We may see some No impact. The promise of AI is
limited or no impact of AI and machine learning number of practices are likely to adopt
AI tools over the next three years.
adoption of AI tools among select
rheumatology practices.
mostly theoretical at this point.
on rheumatology care in the next three years.
N = 87
26 27AI / MACHINE LEARNING
THE LONGER VIEW: Looking longer-term, participating
rheumatologists are generally pessimistic about the potential
of AI/machine learning, with less than half believing it is likely
or very likely to improve quality of care, drive operational
efficiencies, enhance clinical outcomes or lower costs.
Improve quality of care Drive operational efficiencies
8% 15%
Very likely Very likely
25% 26%
Likely Likely
40% 43%
Somewhat likely Somewhat likely
21% 11%
Unlikely Unlikely
6% 5%
Very unlikely Very unlikely
Enhance clinical outcomes Lower costs
13% 10%
Very likely Very likely
21% 15%
Likely Likely
40% 36%
Somewhat likely Somewhat likely
19% 32%
Unlikely Unlikely
7% 7%
Very unlikely Very unlikely
N = 87
28 29AI / MACHINE LEARNING
POTENTIAL AI BENEFITS: About one quarter of participating
rheumatologists can envision AI playing an important role
in treatment decisions, but 46% say it could provide value in
automating administrative tasks.
When it comes to using AI/machine learning to support treatment decisions, which of
the following best reflects your view?
27% 64% 9%
I can envision AI playing an important AI tools may provide some useful I would not use an AI tool to support
role in informing my treatment information, but ultimately, I would rely my treatment decisions
decisions, particularly as treatment on my own training and judgment to
options grow more complex guide treatment decisions
N = 87
Which of the following would be the most valuable benefit that AI/machine learning
could deliver to your practice?
Automating administrative tasks
so I can focus on patients 46%
Identifying best treatment path so patients
get the right drug the first time 18%
Predicting patients most likely to develop
complications or experience adverse events 13%
Accelerating diagnosis so patients
can start treatment sooner 12%
Automating functions that are currently staffed
by people, allowing my practice to save money 9%
Predicting patients most likely to be
non-adherent to therapy 2%
N = 87
30 31Contributors About Cardinal Health Specialty
Gordon K. Lam, MD, FACR Solutions
Medical Director of Clinical Research
Cardinal Health Specialty Solutions is an experienced team of
Arthritis & Osteoporosis Consultants of the Carolinas
trusted advisors developing solutions for the opportunities
Amy Valley, PharmD and challenges facing biopharma companies and healthcare
Vice President, Clinical Strategy and Technology Solutions providers. We enhance product success on the path to approval,
Cardinal Health Specialty Solutions launch and commercialization with configurable, integrated
offers to meet unique needs. We also deliver knowledge, scale
A note from our medical team and proven technology to enable providers to deliver high-
quality and efficient patient care. For rheumatologists, these
We hope you enjoy the second issue of Rheumatology Insights, services are delivered through Cornerstone Rheumatology™ GPO.
a publication based on our research with rheumatologists
across the U.S.
References
As Cardinal Health Specialty Solutions continues to expand 1 Price L, Melendez G, Pouliot P. Lasting COVID-19 Impacts on US Rheumatology
its work across a range of therapeutic areas, we are pleased Practices [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).
to collaborate with leading clinical experts like Gordon Lam, 2 Seppen B, L’ami M, dos Santos Rico S, et al. A Smartphone App for Self-Monitoring
MD. Dr. Lam, who currently serves as Medical Director of of Rheumatoid Arthritis Disease Activity to Assist Patient-Initiated Care: Protocol
Clinical Research, Arthritis and Osteoporosis Consultants of for a Randomized Controlled Trial [abstract]. JMIR Research Protocols. 2020, 02; (9).
the Carolinas, has worked with Cardinal Health for the past 3 Haberman R, Herati R, Simon D et al. Methotrexate hampers immunogenicity to
three years on research and education projects that create BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
Annals of the Rheumatic Diseases. 2021;80:1339-1344.
value for rheumatology practices, healthcare providers and
pharmaceutical manufacturers. In this issue of Rheumatology 4 Rheumatology Patients on Immunosuppressive Medications Qualify for Third
Insights, Dr. Lam brings his expert perspective to our sections COVID-19 Vaccine Dose. https://www.rheumatology.org/About-Us/Newsroom/
Press-Releases/ID/1159.
on COVID-19 and the changing reimbursement landscape.
5 July 2021 Quarterly Average Sales Price (ASP) Medicare Part B Drug Pricing
We are also proud to share an expert perspective from our Files and Revisions to Prior Quarterly Pricing Files. https://www.cms.gov/files/
colleague, Amy Valley, PharmD, who serves as Vice President document/mm12244.pdf. Accessed
of Clinical Strategy and Technology Solutions. Amy has 6, 9 FDA requires warnings about increased risk of serious heart-related events, cancer,
spent much of the past year developing and launching new blood clots, and death for JAK inhibitors that treat certain chronic inflammatory
conditions. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-
technology solutions to help community practices achieve
warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-
better performance in value-based care. We couldn’t think of and-death.
anyone better to expound on our artificial intelligence and
7, 10 Pandemic surge causes major shortage of a drug that treats rheumatoid arthritis
technology research. and severe Covid-19. https://www.cnn.com/2021/08/27/health/actemra-shortage-
rheumatoid-arthritis-covid/index.html.
As always, we look forward to hearing your thoughts and
feedback on our work. 8 Fayad F, Ziade NR, Merheb G, et al. Patient preferences for rheumatoid arthritis
treatments: results from the national cross-sectional LERACS study. Patient Prefer
Bruce Feinberg, DO Ajeet Gajra, MD, MBBS, FACP Adherence. 2018;12:1619–1625.
Vice President Vice President 11 Ringsted S, Sathe N, Deodhar A, Choi D. An Artificial Intelligence (AI) Assistant
Chief Medical Officer Chief Medical Officer Identifying Spinal Diffuse Idiopathic Skeletal Hyperostosis on Plain X-rays: A Pilot
Deep Learning Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).
Methodology
12 Rehberg M, Giegerich C, Praestgaard A, et al. Identification of a Rule to Predict
Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine
Learning and Clinical Trial Data [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).
The research was fielded using web-based surveys from July
through September 2021. More than 85 rheumatologists 13 Webster D, Haberman R, Perez-Chada L, et al. Development and Preliminary
Validation of Smartphone Sensor-based Measurement Tools for Psoriatic Arthritis
from a mix of community- and hospital-based practices
[abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).
participated in the research.
Let’s explore how we can help.
specialtysolutions@cardinalhealth.com
Biopharma: cardinalhealth.com/specialtysolutions
Providers: cardinalhealth.com/cornerstonerheumatology
©2021 Cardinal Health. All Rights Reserved. CARDINAL HEALTH, CORNERSTONE RHEUMATOLOGY, and the Cardinal Health LOGO are trademarks
or registered trademarks of Cardinal Health. All other marks are the property of their respective owners. Lit. No. 1SS21-1675909.You can also read
